Form 4: AVADEL Director Transfers 11,000 Stock Options to Trust

AVADEL PHARMACEUTICALS PLC Director Geoffrey Michael Glass transferred 11,000 stock options with an exercise price of $10.83 to a revocable trust on September 15, 2025.

Summary

• Geoffrey Michael Glass, a Director of AVADEL PHARMACEUTICALS PLC, reported a change in the form of beneficial ownership of stock options.
• On September 15, 2025, Glass transferred 11,000 stock options to the Geoffrey M. Glass Revocable Trust u/t/d August 26, 2020.
• The transferred stock options have an exercise price of $10.83 per share.
• These options are scheduled to vest in full on the earlier of July 29, 2026, or the date of the next annual general meeting of shareholders, contingent on Glass's continued service.
• The expiration date for these stock options is July 29, 2035.
• Glass serves as the trustee of the revocable trust, and he, along with members of his immediate family, are the sole beneficiaries, maintaining his indirect beneficial ownership.

Sentiment

Score: 5

Explanation: The sentiment is neutral. This filing reports a routine insider transaction involving the transfer of stock options to a revocable trust for estate planning purposes. It does not indicate any change in the insider's economic interest in the company or provide new information about the company's performance or prospects.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding the company's operational or financial performance.

Industry Context

This Form 4 filing reports an insider transaction, specifically a transfer of stock options to a trust, which is a routine disclosure for executive compensation and estate planning. It does not reflect broader industry trends or competitive positioning.

Related Party Transactions

• On September 15, 2025, Geoffrey Michael Glass transferred 11,000 stock options to the Geoffrey M. Glass Revocable Trust, of which he is the trustee and he and his immediate family are the sole beneficiaries. This constitutes a transaction between the reporting person and an entity he controls and benefits from.

Stakeholder Impact

• Shareholders: Minimal direct impact as the beneficial ownership of the options remains with the director and his immediate family, indicating no change in the director's economic exposure to the company.

Next Steps

• Vesting of the 11,000 stock options on the earlier of July 29, 2026, or the next annual general meeting, subject to continued service.

Key Dates

Keywords

AVDL, Avadel Pharmaceuticals, Stock Options, Insider Transaction, Form 4, Geoffrey Glass, Beneficial Ownership, Trust Transfer